PERCEPTRONIX RECEIVES CE MARK FOR ITS CLEARSIGN SPUTUM TEST FOR EARLY LUNG CANCER

Perceptronix Medical Inc. May 26 announced receipt of CE Mark for its ClearSign Sputum Test for the detection of early lung cancer, allowing it to be marketed in the European Union.
Genetic Engineering News